Effect of Helicobacter pylori eradication on insulin resistance, serum lipids and low-grade inflammation.

Abstract

BACKGROUND/AIM:

Many studies have revealed a close relationship between Helicobacter pylori (HP) infection and insulin resistance. The aim of this study was to investigate the effects of HP eradication on insulin resistance, serum lipids and low-grade inflammation.

MATERIALS AND METHODS:

This was a prospective, open-label, single-center study which consisted of 159 patients. The patients with HP infection received a 14-day sequential regimen. A HOMA-IR (homeostasis model assessment of insulin resistance) level was used to assess insulin resistance.

RESULTS:

Eighty-eight patients with HP infection and seventy-one patients without HP infection were studied. HOMA-IR, total cholesterol (TC), triglyceride (TG), LDL cholesterol (LDL-C) and C reactive protein (CRP) levels were significantly higher and HDL-cholesterol (HDL-C) levels were significantly lower in patients with HP infection compared to the patients without HP infection (P<0.05). The HP eradication rates with a sequential regimen in dyspeptic patients were 53.4%. Six weeks after the end of eradication therapy, the mean fasting insulin, HOMA-IR, TC, TG, LDL-C, and CRP levels in patients with successful eradication were significantly decreased from the pretreatment levels (P<0.05) and HDL-C level was significantly increased from the pretreatment levels (P<0.05). The mean fasting insulin, HOMA-IR, TC, TG, LDL-C, CRP levels and HDL-C levels in patients with unsuccessful eradication were not significantly changed from pretreatment levels (P<0.05).

CONCLUSION:

This study showed beneficial effects of HP eradication on insulin resistance, atherogenic lipid abnormalities and low-grade inflammation. The results suggest that HP eradication may prevent coronary artery disease and metabolic syndrome.

• Authors: Ramazan Gen, Mehmet Demir, Hilmi Ataseven
• Journal: Southern medical journal (South Med J) Vol. 103 Issue 3 Pg. 190-6 (Mar 2010) ISSN: 1541-8243 [Electronic] United States
• PMID: 20134372 (Publication Type: Journal Article)

Chemical References

• 2-Pyridinylmethylsulfinylbenzimidazoles
• Anti-Bacterial Agents
• Lipids
• Proton Pump Inhibitors
• Metronidazole
• Amoxicillin
• C-Reactive Protein
• Pantoprazole

Topics

• 2-Pyridinylmethylsulfinylbenzimidazoles (therapeutic use)
• Adult
• Amoxicillin (therapeutic use)
• Anti-Bacterial Agents (therapeutic use)
• C-Reactive Protein (metabolism)
• Case-Control Studies
• Female
• Helicobacter Infections (drug therapy, immunology, physiopathology)
• Helicobacter pylori
• Humans
• Inflammation (microbiology)
• Insulin Resistance (physiology)
• Lipids (blood)
• Male
• Metronidazole (therapeutic use)
• Pantoprazole
• Prospective Studies
• Proton Pump Inhibitors (therapeutic use)